董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Roger A. Jeffs | 男 | Director and Chief Executive Officer | 63 | 未披露 | 未持股 | 2025-07-01 |
| Arthur Kirsch | 男 | Director | 73 | 7.68万美元 | 未持股 | 2025-07-01 |
| Raman Singh | 男 | Director | 54 | 9.70万美元 | 未持股 | 2025-07-01 |
| Stephen Bloch | 男 | Chairperson of the Board and Director | 63 | 10.06万美元 | 未持股 | 2025-07-01 |
| Katie Rielly Gauvin | 女 | Director | 61 | 未披露 | 未持股 | 2025-07-01 |
| David Johnson | 男 | Director | 42 | 未披露 | 未持股 | 2025-07-01 |
| Damian deGoa | 男 | Director | 46 | 未披露 | 未持股 | 2025-07-01 |
| Paul B. Manning | 男 | Director | 69 | 未披露 | 未持股 | 2025-07-01 |
| Joanna Horobin | 女 | Director | 70 | 5.75万美元 | 未持股 | 2025-07-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Roger A. Jeffs | 男 | Director and Chief Executive Officer | 63 | 未披露 | 未持股 | 2025-07-01 |
| Jason Adair | 男 | Chief Business Officer | 53 | 未披露 | 未持股 | 2025-07-01 |
| Michael Kaseta | 男 | Chief Operating Officer and Chief Financial Officer | 49 | 未披露 | 未持股 | 2025-07-01 |
| Rajeev Saggar | 男 | Chief Medical Officer | -- | 未披露 | 未持股 | 2025-07-01 |
| Scott Moomaw | 男 | Chief Commercial Officer | -- | 未披露 | 未持股 | 2025-07-01 |
| Russell Schundler | 男 | General Counsel and Secretary | -- | 未披露 | 未持股 | 2025-07-01 |
| Dana Boyle | 女 | Chief Accounting Officer | 41 | 未披露 | 未持股 | 2025-07-01 |
董事简历
中英对照 | 中文 | 英文- Roger A. Jeffs
-
RogerA.Jeffs自2017年5月以来一直担任我们的董事会成员。Jeffs博士于2016年6月以United Therapeutics Corporation总裁的身份退休。在退休之前，Jeffs博士曾于2001年至2016年6月担任United Therapeutics Corporation的联席首席执行官。Jeffs博士于1998年9月加入United Therapeutics Corporation，担任研究、开发和医疗总监，并于2001年4月至2014年12月担任其首席运营官。Jeffs博士于2001年至2016年6月担任United Therapeutics Corporation的董事，目前还担任其他三家上市公司的董事会成员:AlbireoPharma，Inc.，Axsome Therapeutics和SangamoTherapeutics，Inc.Jeffs博士拥有杜克大学（Duke University）化学学士学位和北卡罗莱纳大学（University of North Carolina）药理学博士学位。
Roger A. Jeffs,has been Chief Executive Officer since January 2022 and a member of Board of Directors since November 2020. Dr. Jeffs served on Compensation Committee from November 2020 to December 2021 and on Liquidia Corporation Research and Development Committee and Litigation Committee from April 2021 to January 2022. Dr. Jeffs also served as a director of RareGen from August 2018 until November 2020. Dr. Jeffs is currently the Co-Founder and Vice Chairman of Kriya Therapeutics, a gene therapy company, where he has served since October 2019. Dr. Jeffs was previously at United Therapeutics Corporation, a biotechnology company, where he worked for 18 years until 2016. Dr. Jeffs joined United Therapeutics Corporation during its inception phase in 1998 as Director of Research, Development, and Medical and served as its President and Chief Operating Officer from 2001 to 2014, and President and co-CEO from 2015-2016, and was a member of the board of directors from 2001 through 2016. While at United Therapeutics, Dr. Jeffs helped lead the initial public offering, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to a consistent >20% CAGR and $1.5 billion revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs previously held positions at Amgen, Inc., a biopharmaceutical company, and Burroughs Wellcome Co., a pharmaceutical company, where he held roles in clinical development. Dr. Jeffs currently serves on the board of directors of Axsome Therapeutics, Inc. (Nasdaq: AXSM) and previously served, within the last five years, on the board of directors of Albireo Pharma, Inc. (Nasdaq: ALBO). Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine. - RogerA.Jeffs自2017年5月以来一直担任我们的董事会成员。Jeffs博士于2016年6月以United Therapeutics Corporation总裁的身份退休。在退休之前，Jeffs博士曾于2001年至2016年6月担任United Therapeutics Corporation的联席首席执行官。Jeffs博士于1998年9月加入United Therapeutics Corporation，担任研究、开发和医疗总监，并于2001年4月至2014年12月担任其首席运营官。Jeffs博士于2001年至2016年6月担任United Therapeutics Corporation的董事，目前还担任其他三家上市公司的董事会成员:AlbireoPharma，Inc.，Axsome Therapeutics和SangamoTherapeutics，Inc.Jeffs博士拥有杜克大学（Duke University）化学学士学位和北卡罗莱纳大学（University of North Carolina）药理学博士学位。
- Roger A. Jeffs,has been Chief Executive Officer since January 2022 and a member of Board of Directors since November 2020. Dr. Jeffs served on Compensation Committee from November 2020 to December 2021 and on Liquidia Corporation Research and Development Committee and Litigation Committee from April 2021 to January 2022. Dr. Jeffs also served as a director of RareGen from August 2018 until November 2020. Dr. Jeffs is currently the Co-Founder and Vice Chairman of Kriya Therapeutics, a gene therapy company, where he has served since October 2019. Dr. Jeffs was previously at United Therapeutics Corporation, a biotechnology company, where he worked for 18 years until 2016. Dr. Jeffs joined United Therapeutics Corporation during its inception phase in 1998 as Director of Research, Development, and Medical and served as its President and Chief Operating Officer from 2001 to 2014, and President and co-CEO from 2015-2016, and was a member of the board of directors from 2001 through 2016. While at United Therapeutics, Dr. Jeffs helped lead the initial public offering, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to a consistent >20% CAGR and $1.5 billion revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs previously held positions at Amgen, Inc., a biopharmaceutical company, and Burroughs Wellcome Co., a pharmaceutical company, where he held roles in clinical development. Dr. Jeffs currently serves on the board of directors of Axsome Therapeutics, Inc. (Nasdaq: AXSM) and previously served, within the last five years, on the board of directors of Albireo Pharma, Inc. (Nasdaq: ALBO). Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.
- Arthur Kirsch
-
Arthur Kirsch自2016年9月起担任董事会成员，自2016年8月成立以来担任审计委员会主席，自2019年5月起担任薪酬委员会成员。从2004年5月到2016年2月，Kirsch先生担任PozenInc.的董事纳斯达克股票代码:POZN。Kirsch先生于2016年2月至2019年5月担任Aralez Pharmaceuticals，Inc.（纳斯达克股票代码:ARLZ）的董事。Kirsch先生目前是Kadmon Corporation（NYSE:KDMN）的董事，自2019年5月起担任该职位。2015年8月至2016年10月，Kirsch先生担任Immunomedics，Inc.（纳斯达克股票代码:IMMU）的董事。从2005年6月至2020年4月，Kirsch先生担任全球投资银行公司GCA Global，LLC的董事总经理兼高级顾问以及医疗设备和诊断全球主管。从1994年5月到2004年5月，他曾担任Vector Securities公司（经纪公司）的执行Vice President、研究主管。从1990年2月到1993年5月，Kirsch先生担任NatWest Securities Limited的总裁，这是一家经纪公司。1979年6月至1990年2月，Kirsch先生在Drexel Burnham Lambert，Inc.（一家投资银行公司）工作，担任执行Vice President和股票部门主管。Kirsch先生毕业于罗德岛大学（University of Rhode Island），获得理学学士学位，还持有巴鲁克学院（Baruch College）的工商管理硕士学位。
Arthur Kirsch has served as a member of board of directors since inception in April 2020. Mr. Kirsch is a Managing Partner at TPG Growth, a private equity firm, and has been with TPG since 2007. Prior to TPG, Mr. Kirsch was a Principal at Warburg Pinc, a private equity firm, from 2003 to 2007. - Arthur Kirsch自2016年9月起担任董事会成员，自2016年8月成立以来担任审计委员会主席，自2019年5月起担任薪酬委员会成员。从2004年5月到2016年2月，Kirsch先生担任PozenInc.的董事纳斯达克股票代码:POZN。Kirsch先生于2016年2月至2019年5月担任Aralez Pharmaceuticals，Inc.（纳斯达克股票代码:ARLZ）的董事。Kirsch先生目前是Kadmon Corporation（NYSE:KDMN）的董事，自2019年5月起担任该职位。2015年8月至2016年10月，Kirsch先生担任Immunomedics，Inc.（纳斯达克股票代码:IMMU）的董事。从2005年6月至2020年4月，Kirsch先生担任全球投资银行公司GCA Global，LLC的董事总经理兼高级顾问以及医疗设备和诊断全球主管。从1994年5月到2004年5月，他曾担任Vector Securities公司（经纪公司）的执行Vice President、研究主管。从1990年2月到1993年5月，Kirsch先生担任NatWest Securities Limited的总裁，这是一家经纪公司。1979年6月至1990年2月，Kirsch先生在Drexel Burnham Lambert，Inc.（一家投资银行公司）工作，担任执行Vice President和股票部门主管。Kirsch先生毕业于罗德岛大学（University of Rhode Island），获得理学学士学位，还持有巴鲁克学院（Baruch College）的工商管理硕士学位。
- Arthur Kirsch has served as a member of board of directors since inception in April 2020. Mr. Kirsch is a Managing Partner at TPG Growth, a private equity firm, and has been with TPG since 2007. Prior to TPG, Mr. Kirsch was a Principal at Warburg Pinc, a private equity firm, from 2003 to 2007.
- Raman Singh
-
Raman Singh自2018年2月起担任董事会成员，自2018年7月起担任审计委员会成员，自2018年7月成立以来担任提名和公司治理委员会成员。自2011年10月以来，Singh先生一直担任MundiPharma Pte Limited的首席执行官，该公司是活跃在镇痛，肿瘤学，眼科，呼吸，专科护理和消费者健康领域的独立联营公司网络的一部分。Singh先生于1992年毕业于奥斯曼尼亚大学（Osmania University），获得机械工程学士学位。他还持有Thunderbird School of Global Management的国际管理硕士学位和Assumption University的工商管理硕士学位。
Raman Singh has been a member of our Board since February 2018 a member of our Audit Committee since July 2018 and a member of our Nominating and Corporate Governance Committee since its formation in July 2018. Since October 2011 Mr. Singh has served as the chief executive officer of Mundipharma Pte Limited, which is part of a network of independent associated companies active in the fields of analgesia, oncology, ophthalmology, respiratory, specialty care and consumer health. Mr. Singh graduated from Osmania University with a Bachelors in Mechanical Engineering in 1992. He also holds Masters in International Management from Thunderbird School of Global Management and in Business Administration from Assumption University. - Raman Singh自2018年2月起担任董事会成员，自2018年7月起担任审计委员会成员，自2018年7月成立以来担任提名和公司治理委员会成员。自2011年10月以来，Singh先生一直担任MundiPharma Pte Limited的首席执行官，该公司是活跃在镇痛，肿瘤学，眼科，呼吸，专科护理和消费者健康领域的独立联营公司网络的一部分。Singh先生于1992年毕业于奥斯曼尼亚大学（Osmania University），获得机械工程学士学位。他还持有Thunderbird School of Global Management的国际管理硕士学位和Assumption University的工商管理硕士学位。
- Raman Singh has been a member of our Board since February 2018 a member of our Audit Committee since July 2018 and a member of our Nominating and Corporate Governance Committee since its formation in July 2018. Since October 2011 Mr. Singh has served as the chief executive officer of Mundipharma Pte Limited, which is part of a network of independent associated companies active in the fields of analgesia, oncology, ophthalmology, respiratory, specialty care and consumer health. Mr. Singh graduated from Osmania University with a Bachelors in Mechanical Engineering in 1992. He also holds Masters in International Management from Thunderbird School of Global Management and in Business Administration from Assumption University.
- Stephen Bloch
-
Stephen Bloch，他一直担任Liquidia Technologies, Inc.的董事会主席（2018年10月以来），以及Liquidia Technologies, Inc.的董事会成员（2009年7月以来），审计委员会成员（2016年8月成立以来），薪酬委员会主席（2016年8月成立以来）。Bloch博士目前是一些私人生命科学公司的董事，并担任Marinus Pharmaceuticals, Inc.的董事。纳斯达克：2005年9月至2016年4月期间的MRNS。2007年11月以来，他一直是Canaan Partners（全球风险投资公司）的普通合伙人。从2003年8月到2007年11月，Bloch博士是Canaan Partners的负责人。从1995年1月到2002年6月，他是Radiology Management Sciences, LLC（专业医疗管理公司）的创始人和首席执行官。他毕业于达特茅斯学院，获得文学学士学位。他还获得了罗切斯特大学（University of Rochester）的医学博士学位和哈佛大学（Harvard University）的科学和公共政策史文学硕士学位。
Stephen Bloch,has been the Chairperson and member of Board, and a member of Audit Committee, since Liquidia Corporation's formation in June 2020 and has served as a member and Chairperson of Nominating and Corporate Governance Committee since April 2021. Previously, Dr. Bloch served as a member of Liquidia Corporation Litigation Committee from August 2020 to January 2022 and as a member of Liquidia Corporation Research and Development Committee from April 2021 to January 2022. Dr. Bloch has been a member of the board of directors of Liquidia Technologies since July 2009. Dr. Bloch is currently a director of a number of private life sciences companies and served as a director of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) from September 2005 until April 2016. Dr. Bloch has served as Chief Executive Officer of EvolveImmue Therapeutics since January 2020 and as Chief Executive Officer of Allyx Therapeutics, Inc. since July 2020. Dr. Bloch has also been a general partner at Canaan Partners, a global venture capital firm, since November 2007. From August 2003 to November 2007, Dr. Bloch was a principal at Canaan Partners. From January 1995 to June 2002, Dr. Bloch was the founder and chief executive officer of Radiology Management Sciences, LLC, a specialty medical management company. Dr. Bloch graduated from Dartmouth College with a Bachelor of Arts. Dr. Bloch also holds a Doctor of Medicine from the University of Rochester and a Master of Arts in the History of Science from Harvard University. - Stephen Bloch，他一直担任Liquidia Technologies, Inc.的董事会主席（2018年10月以来），以及Liquidia Technologies, Inc.的董事会成员（2009年7月以来），审计委员会成员（2016年8月成立以来），薪酬委员会主席（2016年8月成立以来）。Bloch博士目前是一些私人生命科学公司的董事，并担任Marinus Pharmaceuticals, Inc.的董事。纳斯达克：2005年9月至2016年4月期间的MRNS。2007年11月以来，他一直是Canaan Partners（全球风险投资公司）的普通合伙人。从2003年8月到2007年11月，Bloch博士是Canaan Partners的负责人。从1995年1月到2002年6月，他是Radiology Management Sciences, LLC（专业医疗管理公司）的创始人和首席执行官。他毕业于达特茅斯学院，获得文学学士学位。他还获得了罗切斯特大学（University of Rochester）的医学博士学位和哈佛大学（Harvard University）的科学和公共政策史文学硕士学位。
- Stephen Bloch,has been the Chairperson and member of Board, and a member of Audit Committee, since Liquidia Corporation's formation in June 2020 and has served as a member and Chairperson of Nominating and Corporate Governance Committee since April 2021. Previously, Dr. Bloch served as a member of Liquidia Corporation Litigation Committee from August 2020 to January 2022 and as a member of Liquidia Corporation Research and Development Committee from April 2021 to January 2022. Dr. Bloch has been a member of the board of directors of Liquidia Technologies since July 2009. Dr. Bloch is currently a director of a number of private life sciences companies and served as a director of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) from September 2005 until April 2016. Dr. Bloch has served as Chief Executive Officer of EvolveImmue Therapeutics since January 2020 and as Chief Executive Officer of Allyx Therapeutics, Inc. since July 2020. Dr. Bloch has also been a general partner at Canaan Partners, a global venture capital firm, since November 2007. From August 2003 to November 2007, Dr. Bloch was a principal at Canaan Partners. From January 1995 to June 2002, Dr. Bloch was the founder and chief executive officer of Radiology Management Sciences, LLC, a specialty medical management company. Dr. Bloch graduated from Dartmouth College with a Bachelor of Arts. Dr. Bloch also holds a Doctor of Medicine from the University of Rochester and a Master of Arts in the History of Science from Harvard University.
- Katie Rielly Gauvin
-
Katie Rielly Gauvin，自Liquidia Corporation于2020年6月成立以来，一直是董事会成员以及提名和公司治理委员会成员。Rielly-Gauvin女士还自2022年1月起担任薪酬委员会成员。此前，Rielly-Gauvin女士于2020年6月至2022年1月担任研发委员会主席，并于2020年8月至2022年1月担任诉讼委员会成员。Rielly-Gauvin女士自2019年10月起担任Liquidia技术的董事会成员，并自2019年10月起担任Liquidia技术提名和公司治理委员会以及研究与发展委员会的成员，直至合并交易（定义见下文）于2020年11月完成。Rielly-Gauvin女士于2013年1月至2023年8月期间担任制药研发公司艾伯维公司（纽约证券交易所代码：ABBV）（“艾伯维”）的全球商业发展副总裁。在她任职期间，她监督并领导了免疫学、肿瘤学、神经科学和专科治疗领域的战略方向和扩张，以及管道的商业战略和发展。在加入艾伯维之前，Rielly-Gauvin女士曾在强生公司家族中担任过商业、医疗事务和研究方面的各种职务，包括杨森商业CNS组织的副总裁兼总经理。Rielly-Gauvin女士拥有西蒙斯大学化学理学学士学位和罗格斯大学经济学MBA学位。
Katie Rielly Gauvin,has been a member of Board and a member of Nominating and Corporate Governance Committee since Liquidia Corporation's formation in June 2020. Ms. Rielly-Gauvin has also served on Compensation Committee since January 2022. Previously, Ms. Rielly-Gauvin served as Chairperson of Research and Development Committee from June 2020 to January 2022 and as a member of Litigation Committee from August 2020 to January 2022. Ms. Rielly-Gauvin has been a member of the board of directors of Liquidia Technologies since October 2019 and served as a member of the Liquidia Technologies Nominating and Corporate Governance Committee and Research and Development Committee from October 2019 until consummation of the Merger Transaction (as defined below) in November 2020. Ms. Rielly-Gauvin served as the Vice President of Global Commercial Development of AbbVie Inc. (NYSE: ABBV) ("AbbVie"), a pharmaceutical research and development company from January 2013 until August 2023. During her tenure, she oversaw and led the strategic direction and expansion of the Immunology, Oncology, Neuroscience and Specialty Therapeutics areas, as well as the commercial strategy and development for the pipeline. Prior to joining AbbVie, Ms. Rielly-Gauvin worked in the Johnson & Johnson family of companies across a variety of roles in commercial, medical affairs and research capacities, including Vice President and General Manager for the Janssen Commercial CNS organization. Ms. Rielly-Gauvin holds a Bachelor of Science degree in Chemistry from Simmons University and an MBA in Economics from Rutgers University. - Katie Rielly Gauvin，自Liquidia Corporation于2020年6月成立以来，一直是董事会成员以及提名和公司治理委员会成员。Rielly-Gauvin女士还自2022年1月起担任薪酬委员会成员。此前，Rielly-Gauvin女士于2020年6月至2022年1月担任研发委员会主席，并于2020年8月至2022年1月担任诉讼委员会成员。Rielly-Gauvin女士自2019年10月起担任Liquidia技术的董事会成员，并自2019年10月起担任Liquidia技术提名和公司治理委员会以及研究与发展委员会的成员，直至合并交易（定义见下文）于2020年11月完成。Rielly-Gauvin女士于2013年1月至2023年8月期间担任制药研发公司艾伯维公司（纽约证券交易所代码：ABBV）（“艾伯维”）的全球商业发展副总裁。在她任职期间，她监督并领导了免疫学、肿瘤学、神经科学和专科治疗领域的战略方向和扩张，以及管道的商业战略和发展。在加入艾伯维之前，Rielly-Gauvin女士曾在强生公司家族中担任过商业、医疗事务和研究方面的各种职务，包括杨森商业CNS组织的副总裁兼总经理。Rielly-Gauvin女士拥有西蒙斯大学化学理学学士学位和罗格斯大学经济学MBA学位。
- Katie Rielly Gauvin,has been a member of Board and a member of Nominating and Corporate Governance Committee since Liquidia Corporation's formation in June 2020. Ms. Rielly-Gauvin has also served on Compensation Committee since January 2022. Previously, Ms. Rielly-Gauvin served as Chairperson of Research and Development Committee from June 2020 to January 2022 and as a member of Litigation Committee from August 2020 to January 2022. Ms. Rielly-Gauvin has been a member of the board of directors of Liquidia Technologies since October 2019 and served as a member of the Liquidia Technologies Nominating and Corporate Governance Committee and Research and Development Committee from October 2019 until consummation of the Merger Transaction (as defined below) in November 2020. Ms. Rielly-Gauvin served as the Vice President of Global Commercial Development of AbbVie Inc. (NYSE: ABBV) ("AbbVie"), a pharmaceutical research and development company from January 2013 until August 2023. During her tenure, she oversaw and led the strategic direction and expansion of the Immunology, Oncology, Neuroscience and Specialty Therapeutics areas, as well as the commercial strategy and development for the pipeline. Prior to joining AbbVie, Ms. Rielly-Gauvin worked in the Johnson & Johnson family of companies across a variety of roles in commercial, medical affairs and research capacities, including Vice President and General Manager for the Janssen Commercial CNS organization. Ms. Rielly-Gauvin holds a Bachelor of Science degree in Chemistry from Simmons University and an MBA in Economics from Rutgers University.
- David Johnson
-
David Johnson，被任命为董事会和审计委员会成员。此前，从2021年4月至2022年1月，约翰逊先生担任研究与发展委员会成员。约翰逊先生是美国证券交易委员会（SEC）注册投资管理公司Caligan的管理合伙人和联合创始人。此前，约翰逊先生是凯雷集团的董事总经理，2010年至2017年任职于该公司。在加入凯雷之前，Johnson先生在摩根士丹利工作了六年，担任信安投资领域的副总裁。Johnson先生目前担任Exelixis, Inc.（纳斯达克：EXEL）的非执行董事以及审计委员会和研发委员会成员。Johnson先生曾于2019年10月至2020年11月担任Amag制药的董事。约翰逊先生曾在哈佛大学基金的执行委员会任职，并且是儿童奖学金基金的董事会成员。约翰逊先生于2004年以优异成绩获得哈佛学院应用数学学士学位，并于2004年获得哈佛学院应用数学硕士学位。
David Johnson,was appointed as a member of Board and Audit Committee. Previously, from April 2021 to January 2022, Mr. Johnson served as a member of Research and Development Committee. Mr. Johnson is the Managing Partner and co-Founder of Caligan, an SEC- registered investment manager. Previously, Mr. Johnson was a Managing Director at The Carlyle Group, where he was employed from 2010 to 2017. Prior to joining Carlyle, Mr. Johnson worked for six years at Morgan Stanley, where he was a Vice President in the Principal Investments area. Mr. Johnson currently serves as a non-executive director and member of the Audit Committee and R&D Committee for Exelixis, Inc. (Nasdaq: EXEL). Mr. Johnson was previously a director of AMAG Pharmaceuticals from October 2019 through November 2020. Mr. Johnson has served on the Executive Committee for the Harvard College Fund and is a member of the board of directors of the Children's Scholarship Fund. Mr. Johnson received his A.B. in Applied Mathematics, cum laude, from Harvard College in 2004 and a S.M. in Applied Mathematics from Harvard College in 2004. - David Johnson，被任命为董事会和审计委员会成员。此前，从2021年4月至2022年1月，约翰逊先生担任研究与发展委员会成员。约翰逊先生是美国证券交易委员会（SEC）注册投资管理公司Caligan的管理合伙人和联合创始人。此前，约翰逊先生是凯雷集团的董事总经理，2010年至2017年任职于该公司。在加入凯雷之前，Johnson先生在摩根士丹利工作了六年，担任信安投资领域的副总裁。Johnson先生目前担任Exelixis, Inc.（纳斯达克：EXEL）的非执行董事以及审计委员会和研发委员会成员。Johnson先生曾于2019年10月至2020年11月担任Amag制药的董事。约翰逊先生曾在哈佛大学基金的执行委员会任职，并且是儿童奖学金基金的董事会成员。约翰逊先生于2004年以优异成绩获得哈佛学院应用数学学士学位，并于2004年获得哈佛学院应用数学硕士学位。
- David Johnson,was appointed as a member of Board and Audit Committee. Previously, from April 2021 to January 2022, Mr. Johnson served as a member of Research and Development Committee. Mr. Johnson is the Managing Partner and co-Founder of Caligan, an SEC- registered investment manager. Previously, Mr. Johnson was a Managing Director at The Carlyle Group, where he was employed from 2010 to 2017. Prior to joining Carlyle, Mr. Johnson worked for six years at Morgan Stanley, where he was a Vice President in the Principal Investments area. Mr. Johnson currently serves as a non-executive director and member of the Audit Committee and R&D Committee for Exelixis, Inc. (Nasdaq: EXEL). Mr. Johnson was previously a director of AMAG Pharmaceuticals from October 2019 through November 2020. Mr. Johnson has served on the Executive Committee for the Harvard College Fund and is a member of the board of directors of the Children's Scholarship Fund. Mr. Johnson received his A.B. in Applied Mathematics, cum laude, from Harvard College in 2004 and a S.M. in Applied Mathematics from Harvard College in 2004.
- Damian deGoa
-
Damian deGoa，自2020年12月起担任董事会成员。deGoa先生于2022年1月至2024年7月期间担任Ottawa Avenue Private Capital的首席运营官。此前，deGoa先生于2020年12月至2022年1月担任首席执行官，并于2018年9月至2020年11月RareGen被公司收购之前，担任公司目前的全资子公司RareGen，LLC（现称为Liquidia PAH）的首席执行官和董事。从2012年12月到2018年9月，deGoa先生担任PBM Capital Group，LLC（“PBM资本”）的董事总经理，在那里他领导了几项组合投资、撤资和运营。2015年4月至2017年4月，deGoa先生担任Breas Medical Group的首席执行官，Breas Medical Group是一家于2017年3月被复星医药收购的PBM Capital投资组合公司，随后于2017年3月至2020年2月担任Breas Medical Group的董事。在加入PBM Capital之前，deGoa先生曾于2007年8月至2012年12月在Perrigo Company担任多个职务，包括国际业务发展主管、Perrigo Company公司营养部门的部门财务主管以及企业发展和RX业务发展总监。deGoa先生拥有密歇根大学经济学和哲学文学士学位和德保罗大学金融工商管理硕士学位。
Damian deGoa,has been a member of Board since December 2020. Mr. deGoa served as Chief Operating Officer at Ottawa Avenue Private Capital from January 2022 to July 2024. Previously, Mr. deGoa served as Chief Executive Officer from December 2020 to January 2022 and as Chief Executive Officer and a director of RareGen, LLC (now known as Liquidia PAH), a current wholly owned subsidiary of the Company ("RareGen"), from September 2018 until RareGen's acquisition by the Company in November 2020. From December 2012 until September 2018, Mr. deGoa was the Managing Director of PBM Capital Group, LLC ("PBM Capital") where he led several portfolio investments, divestments and operations. From April 2015 to April 2017, Mr. deGoa served as Chief Executive Officer of Breas Medical Group, a PBM Capital portfolio company which was acquired by Fosun Pharma in March 2017, and subsequently served as a director of Breas Medical Group from March 2017 to February 2020. Prior to joining PBM Capital, Mr. deGoa held various roles at Perrigo Company from August 2007 until December 2012, including Head of International Business Development, Divisional Finance Lead for Perrigo Company's nutrition segment and Director of Corporate Development and Rx Business Development. Mr. deGoa holds a Bachelor of Arts in Economics and Philosophy from the University of Michigan and a Master's in Business Administration in Finance from DePaul University. - Damian deGoa，自2020年12月起担任董事会成员。deGoa先生于2022年1月至2024年7月期间担任Ottawa Avenue Private Capital的首席运营官。此前，deGoa先生于2020年12月至2022年1月担任首席执行官，并于2018年9月至2020年11月RareGen被公司收购之前，担任公司目前的全资子公司RareGen，LLC（现称为Liquidia PAH）的首席执行官和董事。从2012年12月到2018年9月，deGoa先生担任PBM Capital Group，LLC（“PBM资本”）的董事总经理，在那里他领导了几项组合投资、撤资和运营。2015年4月至2017年4月，deGoa先生担任Breas Medical Group的首席执行官，Breas Medical Group是一家于2017年3月被复星医药收购的PBM Capital投资组合公司，随后于2017年3月至2020年2月担任Breas Medical Group的董事。在加入PBM Capital之前，deGoa先生曾于2007年8月至2012年12月在Perrigo Company担任多个职务，包括国际业务发展主管、Perrigo Company公司营养部门的部门财务主管以及企业发展和RX业务发展总监。deGoa先生拥有密歇根大学经济学和哲学文学士学位和德保罗大学金融工商管理硕士学位。
- Damian deGoa,has been a member of Board since December 2020. Mr. deGoa served as Chief Operating Officer at Ottawa Avenue Private Capital from January 2022 to July 2024. Previously, Mr. deGoa served as Chief Executive Officer from December 2020 to January 2022 and as Chief Executive Officer and a director of RareGen, LLC (now known as Liquidia PAH), a current wholly owned subsidiary of the Company ("RareGen"), from September 2018 until RareGen's acquisition by the Company in November 2020. From December 2012 until September 2018, Mr. deGoa was the Managing Director of PBM Capital Group, LLC ("PBM Capital") where he led several portfolio investments, divestments and operations. From April 2015 to April 2017, Mr. deGoa served as Chief Executive Officer of Breas Medical Group, a PBM Capital portfolio company which was acquired by Fosun Pharma in March 2017, and subsequently served as a director of Breas Medical Group from March 2017 to February 2020. Prior to joining PBM Capital, Mr. deGoa held various roles at Perrigo Company from August 2007 until December 2012, including Head of International Business Development, Divisional Finance Lead for Perrigo Company's nutrition segment and Director of Corporate Development and Rx Business Development. Mr. deGoa holds a Bachelor of Arts in Economics and Philosophy from the University of Michigan and a Master's in Business Administration in Finance from DePaul University.
- Paul B. Manning
-
PaulB.Manning自2020年3月以来一直担任我们的董事会成员。Manning先生目前担任PBM Capital Group，LLC的首席执行官，这是一家私募股权投资公司，其业务是投资于梦百合和生命科学相关公司，该公司由他于2010年创立。Manning先生目前担任Verrica PharmaceuticalsInc.公司（一家生物制药公司）董事会主席。此外，他曾于2016年9月至2019年11月担任生物制药公司Dova制药有限公司的董事会成员，并于2014年4月至2018年5月担任基因治疗公司Avexis，Inc.的董事会成员。Manning先生在马萨诸塞大学（University of Massachusetts）获得微生物学学士学位。
Paul B. Manning,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since March 2020. Mr. Manning currently serves as the Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Mr. Manning has served as interim Chief Executive Officer of SalioGen Therapeutics, Inc., a private biopharmaceutical company, since November 2022. Mr. Manning currently serves as Chairman of the board of directors of Verrica Pharmaceuticals Inc., a publicly traded biopharmaceutical company, and on the boards of directors of Liquidia Corporation, a publicly traded biopharmaceutical company, and Candel Therapeutics, Inc., a publicly traded biopharmaceutical company. Additionally, he previously served on the boards of directors of Dova Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2016 to November 2019 and AveXis, Inc., a publicly traded gene therapy company, from 2014 to May 2018. Mr. Manning earned a B.S. in microbiology from the University of Massachusetts. - PaulB.Manning自2020年3月以来一直担任我们的董事会成员。Manning先生目前担任PBM Capital Group，LLC的首席执行官，这是一家私募股权投资公司，其业务是投资于梦百合和生命科学相关公司，该公司由他于2010年创立。Manning先生目前担任Verrica PharmaceuticalsInc.公司（一家生物制药公司）董事会主席。此外，他曾于2016年9月至2019年11月担任生物制药公司Dova制药有限公司的董事会成员，并于2014年4月至2018年5月担任基因治疗公司Avexis，Inc.的董事会成员。Manning先生在马萨诸塞大学（University of Massachusetts）获得微生物学学士学位。
- Paul B. Manning,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since March 2020. Mr. Manning currently serves as the Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Mr. Manning has served as interim Chief Executive Officer of SalioGen Therapeutics, Inc., a private biopharmaceutical company, since November 2022. Mr. Manning currently serves as Chairman of the board of directors of Verrica Pharmaceuticals Inc., a publicly traded biopharmaceutical company, and on the boards of directors of Liquidia Corporation, a publicly traded biopharmaceutical company, and Candel Therapeutics, Inc., a publicly traded biopharmaceutical company. Additionally, he previously served on the boards of directors of Dova Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2016 to November 2019 and AveXis, Inc., a publicly traded gene therapy company, from 2014 to May 2018. Mr. Manning earned a B.S. in microbiology from the University of Massachusetts.
- Joanna Horobin
-
Joanna Horobin，自2020年6月Liquidia Corporation成立以来一直担任董事会成员。从2020年8月到2022年1月，还担任诉讼委员会的成员和成员。Horobin博士自2019年10月起担任Liquidia Technologies的董事会成员。从2015年11月到2019年7月，Horobin博士担任Idera Pharmaceuticals， Inc.的高级副总裁兼首席医疗官，这是一家临床阶段的生物制药公司，专注于肿瘤和罕见疾病适应症（“Idera”）（纳斯达克股票代码：IDRA）的候选药物的临床开发和最终商业化。加入idea之前，曾担任Verastem， Inc.（“Verastem”）（纳斯达克股票代码：VSTM）的首席医疗官，这是一家生物制药公司，专注于开发和商业化药物，以改善癌症患者的生存和生活质量（2012年9月至2015年7月）。2006年9月至2012年9月，她担任Syndax Pharmaceuticals， Inc.（“Syndax”）（纳斯达克股票代码：SNDX）的总裁，这是一家开发创新癌症治疗管道的临床阶段生物制药公司。2006年9月至2012年4月，她担任首席执行官。在此之前，她曾在Rhne Poulenc Rorer（现为赛诺菲）和Chugai Rhne Poulenc等全球制药公司担任多个职位，责任越来越大。她在英国曼彻斯特大学获得医学学位。此前，Horobin博士于2018年4月至2024年6月在Kymera Therapeutics， Inc.（纳斯达克代码：KYMR）董事会任职，于2020年11月至2023年12月在Vyant Bio Inc.（纳斯达克代码：VYNT）董事会任职，以及其他一些私人和非美国上市公司。
Joanna Horobin,has been a member of Board of Directors since Liquidia Corporation's formation in June 2020. Dr. Horobin also served as a member of and as a member of Litigation Committee from August 2020 to January 2022. Dr. Horobin has been a member of the board of directors of Liquidia Technologies since October 2019. Dr. Horobin served as the Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the clinical development, and ultimately the commercialization, of drug candidates for both oncology and rare disease indications ("Idera") (Nasdaq: IDRA), from November 2015 until July 2019. Prior to joining Idera, Dr. Horobin served as the Chief Medical Officer of Verastem, Inc. ("Verastem") (Nasdaq: VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, from September 2012 to July 2015. Prior to joining Verastem, she served as President of Syndax Pharmaceuticals, Inc. ("Syndax") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, from September 2006 to September 2012 and as Chief Executive Officer from September 2006 until April 2012. Prior to that, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhne Poulenc Rorer (now Sanofi) and Chugai Rhne Poulenc. Dr. Horobin received her medical degree from the University of Manchester, England. Dr. Horobin previously served on the board of Kymera Therapeutics, Inc. (Nasdaq: KYMR) from April 2018 to June 2024, on the board of Vyant Bio Inc. (Nasdaq: VYNT) from November 2020 to December 2023, and certain other private and non-US public companies. - Joanna Horobin，自2020年6月Liquidia Corporation成立以来一直担任董事会成员。从2020年8月到2022年1月，还担任诉讼委员会的成员和成员。Horobin博士自2019年10月起担任Liquidia Technologies的董事会成员。从2015年11月到2019年7月，Horobin博士担任Idera Pharmaceuticals， Inc.的高级副总裁兼首席医疗官，这是一家临床阶段的生物制药公司，专注于肿瘤和罕见疾病适应症（“Idera”）（纳斯达克股票代码：IDRA）的候选药物的临床开发和最终商业化。加入idea之前，曾担任Verastem， Inc.（“Verastem”）（纳斯达克股票代码：VSTM）的首席医疗官，这是一家生物制药公司，专注于开发和商业化药物，以改善癌症患者的生存和生活质量（2012年9月至2015年7月）。2006年9月至2012年9月，她担任Syndax Pharmaceuticals， Inc.（“Syndax”）（纳斯达克股票代码：SNDX）的总裁，这是一家开发创新癌症治疗管道的临床阶段生物制药公司。2006年9月至2012年4月，她担任首席执行官。在此之前，她曾在Rhne Poulenc Rorer（现为赛诺菲）和Chugai Rhne Poulenc等全球制药公司担任多个职位，责任越来越大。她在英国曼彻斯特大学获得医学学位。此前，Horobin博士于2018年4月至2024年6月在Kymera Therapeutics， Inc.（纳斯达克代码：KYMR）董事会任职，于2020年11月至2023年12月在Vyant Bio Inc.（纳斯达克代码：VYNT）董事会任职，以及其他一些私人和非美国上市公司。
- Joanna Horobin,has been a member of Board of Directors since Liquidia Corporation's formation in June 2020. Dr. Horobin also served as a member of and as a member of Litigation Committee from August 2020 to January 2022. Dr. Horobin has been a member of the board of directors of Liquidia Technologies since October 2019. Dr. Horobin served as the Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the clinical development, and ultimately the commercialization, of drug candidates for both oncology and rare disease indications ("Idera") (Nasdaq: IDRA), from November 2015 until July 2019. Prior to joining Idera, Dr. Horobin served as the Chief Medical Officer of Verastem, Inc. ("Verastem") (Nasdaq: VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, from September 2012 to July 2015. Prior to joining Verastem, she served as President of Syndax Pharmaceuticals, Inc. ("Syndax") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, from September 2006 to September 2012 and as Chief Executive Officer from September 2006 until April 2012. Prior to that, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhne Poulenc Rorer (now Sanofi) and Chugai Rhne Poulenc. Dr. Horobin received her medical degree from the University of Manchester, England. Dr. Horobin previously served on the board of Kymera Therapeutics, Inc. (Nasdaq: KYMR) from April 2018 to June 2024, on the board of Vyant Bio Inc. (Nasdaq: VYNT) from November 2020 to December 2023, and certain other private and non-US public companies.
高管简历
中英对照 | 中文 | 英文- Roger A. Jeffs
RogerA.Jeffs自2017年5月以来一直担任我们的董事会成员。Jeffs博士于2016年6月以United Therapeutics Corporation总裁的身份退休。在退休之前，Jeffs博士曾于2001年至2016年6月担任United Therapeutics Corporation的联席首席执行官。Jeffs博士于1998年9月加入United Therapeutics Corporation，担任研究、开发和医疗总监，并于2001年4月至2014年12月担任其首席运营官。Jeffs博士于2001年至2016年6月担任United Therapeutics Corporation的董事，目前还担任其他三家上市公司的董事会成员:AlbireoPharma，Inc.，Axsome Therapeutics和SangamoTherapeutics，Inc.Jeffs博士拥有杜克大学（Duke University）化学学士学位和北卡罗莱纳大学（University of North Carolina）药理学博士学位。
Roger A. Jeffs,has been Chief Executive Officer since January 2022 and a member of Board of Directors since November 2020. Dr. Jeffs served on Compensation Committee from November 2020 to December 2021 and on Liquidia Corporation Research and Development Committee and Litigation Committee from April 2021 to January 2022. Dr. Jeffs also served as a director of RareGen from August 2018 until November 2020. Dr. Jeffs is currently the Co-Founder and Vice Chairman of Kriya Therapeutics, a gene therapy company, where he has served since October 2019. Dr. Jeffs was previously at United Therapeutics Corporation, a biotechnology company, where he worked for 18 years until 2016. Dr. Jeffs joined United Therapeutics Corporation during its inception phase in 1998 as Director of Research, Development, and Medical and served as its President and Chief Operating Officer from 2001 to 2014, and President and co-CEO from 2015-2016, and was a member of the board of directors from 2001 through 2016. While at United Therapeutics, Dr. Jeffs helped lead the initial public offering, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to a consistent >20% CAGR and $1.5 billion revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs previously held positions at Amgen, Inc., a biopharmaceutical company, and Burroughs Wellcome Co., a pharmaceutical company, where he held roles in clinical development. Dr. Jeffs currently serves on the board of directors of Axsome Therapeutics, Inc. (Nasdaq: AXSM) and previously served, within the last five years, on the board of directors of Albireo Pharma, Inc. (Nasdaq: ALBO). Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.- RogerA.Jeffs自2017年5月以来一直担任我们的董事会成员。Jeffs博士于2016年6月以United Therapeutics Corporation总裁的身份退休。在退休之前，Jeffs博士曾于2001年至2016年6月担任United Therapeutics Corporation的联席首席执行官。Jeffs博士于1998年9月加入United Therapeutics Corporation，担任研究、开发和医疗总监，并于2001年4月至2014年12月担任其首席运营官。Jeffs博士于2001年至2016年6月担任United Therapeutics Corporation的董事，目前还担任其他三家上市公司的董事会成员:AlbireoPharma，Inc.，Axsome Therapeutics和SangamoTherapeutics，Inc.Jeffs博士拥有杜克大学（Duke University）化学学士学位和北卡罗莱纳大学（University of North Carolina）药理学博士学位。
- Roger A. Jeffs,has been Chief Executive Officer since January 2022 and a member of Board of Directors since November 2020. Dr. Jeffs served on Compensation Committee from November 2020 to December 2021 and on Liquidia Corporation Research and Development Committee and Litigation Committee from April 2021 to January 2022. Dr. Jeffs also served as a director of RareGen from August 2018 until November 2020. Dr. Jeffs is currently the Co-Founder and Vice Chairman of Kriya Therapeutics, a gene therapy company, where he has served since October 2019. Dr. Jeffs was previously at United Therapeutics Corporation, a biotechnology company, where he worked for 18 years until 2016. Dr. Jeffs joined United Therapeutics Corporation during its inception phase in 1998 as Director of Research, Development, and Medical and served as its President and Chief Operating Officer from 2001 to 2014, and President and co-CEO from 2015-2016, and was a member of the board of directors from 2001 through 2016. While at United Therapeutics, Dr. Jeffs helped lead the initial public offering, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to a consistent >20% CAGR and $1.5 billion revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs previously held positions at Amgen, Inc., a biopharmaceutical company, and Burroughs Wellcome Co., a pharmaceutical company, where he held roles in clinical development. Dr. Jeffs currently serves on the board of directors of Axsome Therapeutics, Inc. (Nasdaq: AXSM) and previously served, within the last five years, on the board of directors of Albireo Pharma, Inc. (Nasdaq: ALBO). Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.
- Jason Adair
自2016年1月以来，Jason Adair一直是我们的Vice President，业务发展和战略。2011年8月至2015年12月，Adair先生担任BioCrystPharmaceuticals，Inc.企业发展执行董事纳斯达克股票代码:BCRX。Adair先生拥有维克森林大学（Wake Forest University）的化学理学学士学位和达特茅斯学院塔克商学院（Tuck School of Business at Dartmouth College）的工商管理硕士学位。
Jason Adair,As Chief Business Officer at Liquidia, Mr. Adair is responsible for corporate development activities including strategy, investor relations, communications and pursuit of collaboration and licensing opportunities for the company. Mr. Adair was hired January 2016 by Liquidia Technologies and been serially promoted from Vice President Corporate Development & Strategy, to Senior Vice President Corporate Development & Strategy in 2022, to Chief Business Officer in 2023. Prior to joining Liquidia in 2016, Mr. Adair led business development efforts at BioCryst Pharmaceuticals as their Executive Director of Corporate Development. His work included the commercial launch and subsequent partnering of the company's first FDA approved drug. He also worked at MedImmune and AstraZeneca in roles of increasing responsibility in business development, marketing and operations. Before entering the pharmaceutical industry, Mr. Adair worked as an analytical chemist for Syngenta and served as an officer in the United States Army. He received an M.B.A. from the Tuck School of Business at Dartmouth College and a B.S. in Chemistry from Wake Forest University.- 自2016年1月以来，Jason Adair一直是我们的Vice President，业务发展和战略。2011年8月至2015年12月，Adair先生担任BioCrystPharmaceuticals，Inc.企业发展执行董事纳斯达克股票代码:BCRX。Adair先生拥有维克森林大学（Wake Forest University）的化学理学学士学位和达特茅斯学院塔克商学院（Tuck School of Business at Dartmouth College）的工商管理硕士学位。
- Jason Adair,As Chief Business Officer at Liquidia, Mr. Adair is responsible for corporate development activities including strategy, investor relations, communications and pursuit of collaboration and licensing opportunities for the company. Mr. Adair was hired January 2016 by Liquidia Technologies and been serially promoted from Vice President Corporate Development & Strategy, to Senior Vice President Corporate Development & Strategy in 2022, to Chief Business Officer in 2023. Prior to joining Liquidia in 2016, Mr. Adair led business development efforts at BioCryst Pharmaceuticals as their Executive Director of Corporate Development. His work included the commercial launch and subsequent partnering of the company's first FDA approved drug. He also worked at MedImmune and AstraZeneca in roles of increasing responsibility in business development, marketing and operations. Before entering the pharmaceutical industry, Mr. Adair worked as an analytical chemist for Syngenta and served as an officer in the United States Army. He received an M.B.A. from the Tuck School of Business at Dartmouth College and a B.S. in Chemistry from Wake Forest University.
- Michael Kaseta
Michael Kaseta，自2023年3月起担任董事会成员。Kaseta先生自2020年11月起担任Liquidia Corporation首席财务官。Kaseta先生于2019年1月至2020年11月担任Aerami Therapeutics，Inc.的首席财务官，该公司是一家私营生物技术公司，专注于开发治疗严重呼吸系统疾病（包括肺动脉高压）的改良疗法，并于2018年3月开始担任前专业制药公司（“Aralez”）Aralez制药公司的首席财务官。Aralez于2018年8月申请破产保护，Kaseta先生一直担任Aralez的首席财务官，直到2019年1月离职。Kaseta先生曾于2017年11月至2018年3月担任Aralez的财务主管兼临时首席财务官，并于2016年9月至2017年11月担任公司财务总监。在加入Aralez之前，Kaseta先生曾在专注于人类健康的全球生物制药公司赛诺菲 S.A.担任多个职位，包括2015年4月至2016年9月担任赛诺菲北美全球服务部首席财务官。Kaseta先生曾于2013年1月至2015年4月担任赛诺菲北美制药控制副总裁，于2007年3月至2013年12月担任赛诺菲财务共享服务副总裁，并于2005年至2007年担任技术会计总监。Kaseta先生拥有詹姆斯麦迪逊大学会计学学士学位，是新泽西州的注册会计师（非在职）。
Michael Kaseta,has been a member of the Board since March 2023. Mr. Kaseta has served as Chief Financial Officer of Liquidia Corporation since November 2020. Mr. Kaseta served as Chief Financial Officer of Aerami Therapeutics, Inc., a privately held biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension, from January 2019 until November 2020, and served as Chief Financial Officer of Aralez Pharmaceuticals Inc., a former specialty pharmaceutical company ("Aralez"), beginning in March 2018. Aralez filed for bankruptcy protection in August 2018, and Mr. Kaseta remained Chief Financial Officer of Aralez until his departure in January 2019. Mr. Kaseta previously served as Head of Finance and Interim Chief Financial Officer of Aralez from November 2017 until March 2018 and Corporate Controller from September 2016 until November 2017. Prior to joining Aralez, Mr. Kaseta held various positions at Sanofi S.A., a global biopharmaceutical company focused on human health, including most recently Chief Financial Officer Sanofi North America, Global Services, from April 2015 through September 2016. Mr. Kaseta was previously the Vice President Sanofi NA Pharma Controlling from January 2013 through April 2015, Vice President, Sanofi Financial Shared Services from March 2007 through December 2013 and Director of Technical Accounting from 2005 to 2007. Mr. Kaseta holds a BBA in accounting from James Madison University and is a CPA (inactive) licensed in the state of New Jersey.- Michael Kaseta，自2023年3月起担任董事会成员。Kaseta先生自2020年11月起担任Liquidia Corporation首席财务官。Kaseta先生于2019年1月至2020年11月担任Aerami Therapeutics，Inc.的首席财务官，该公司是一家私营生物技术公司，专注于开发治疗严重呼吸系统疾病（包括肺动脉高压）的改良疗法，并于2018年3月开始担任前专业制药公司（“Aralez”）Aralez制药公司的首席财务官。Aralez于2018年8月申请破产保护，Kaseta先生一直担任Aralez的首席财务官，直到2019年1月离职。Kaseta先生曾于2017年11月至2018年3月担任Aralez的财务主管兼临时首席财务官，并于2016年9月至2017年11月担任公司财务总监。在加入Aralez之前，Kaseta先生曾在专注于人类健康的全球生物制药公司赛诺菲 S.A.担任多个职位，包括2015年4月至2016年9月担任赛诺菲北美全球服务部首席财务官。Kaseta先生曾于2013年1月至2015年4月担任赛诺菲北美制药控制副总裁，于2007年3月至2013年12月担任赛诺菲财务共享服务副总裁，并于2005年至2007年担任技术会计总监。Kaseta先生拥有詹姆斯麦迪逊大学会计学学士学位，是新泽西州的注册会计师（非在职）。
- Michael Kaseta,has been a member of the Board since March 2023. Mr. Kaseta has served as Chief Financial Officer of Liquidia Corporation since November 2020. Mr. Kaseta served as Chief Financial Officer of Aerami Therapeutics, Inc., a privately held biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension, from January 2019 until November 2020, and served as Chief Financial Officer of Aralez Pharmaceuticals Inc., a former specialty pharmaceutical company ("Aralez"), beginning in March 2018. Aralez filed for bankruptcy protection in August 2018, and Mr. Kaseta remained Chief Financial Officer of Aralez until his departure in January 2019. Mr. Kaseta previously served as Head of Finance and Interim Chief Financial Officer of Aralez from November 2017 until March 2018 and Corporate Controller from September 2016 until November 2017. Prior to joining Aralez, Mr. Kaseta held various positions at Sanofi S.A., a global biopharmaceutical company focused on human health, including most recently Chief Financial Officer Sanofi North America, Global Services, from April 2015 through September 2016. Mr. Kaseta was previously the Vice President Sanofi NA Pharma Controlling from January 2013 through April 2015, Vice President, Sanofi Financial Shared Services from March 2007 through December 2013 and Director of Technical Accounting from 2005 to 2007. Mr. Kaseta holds a BBA in accounting from James Madison University and is a CPA (inactive) licensed in the state of New Jersey.
- Rajeev Saggar
Rajeev Saggar，自2022年7月起担任首席医疗官，负责监督公司研究、临床开发、医疗事务和监管事务的各个方面。在加入Liquidia Corporation公司之前，Saggar博士于2020年1月至2022年7月在Theravance Biopharma任职，担任临床开发副总裁，负责监督呼吸道疾病组合的所有阶段临床开发，包括肺纤维化、同种异体移植排斥、哮喘、COPD和COVID-19。此前，Saggar博士还曾于2017年1月至2019年12月担任亚利桑那大学凤凰城医学院肺重症医学科的临时主管，于2015年7月至2019年12月担任凤凰城邦纳大学医学中心肺动脉高压和纤维化项目以及肺移植项目的医疗主任，于2013年7月至2014年12月担任Evolung，LLC（联合治疗的子公司）的总经理，2011年7月至2013年6月担任诺顿胸腔研究所肺移植副主任和晚期肺部疾病医学主任，2008年6月至2011年6月担任加州大学洛杉矶分校肺移植和肺动脉高压项目医学助理教授。Saggar博士获得了加州大学欧文分校的学士学位和医学博士学位。他在加州大学欧文分校完成了内科住院医师实习，在加州大学欧文分校完成了肺部和重症监护研究金，并分别在加州大学圣地亚哥分校和加州大学洛杉矶分校接受了肺动脉高压和肺移植方面的亚专科培训。
Rajeev Saggar,has been Chief Medical Officer since July 2022 and oversees all aspects of research, clinical development, medical affairs, and regulatory affairs for the company. Prior to joining Liquidia Corporation company, Dr. Saggar was at Theravance Biopharma from January 2020 to July 2022, where he served as Vice President of Clinical Development, with oversight of all phases of clinical development across respiratory disease portfolio, including pulmonary fibrosis, allograft rejection, asthma, COPD, and COVID-19. Previously, Dr. Saggar also served as Interim Chief of the Division of Pulmonary Critical Care at University of Arizona, College of Medicine, Phoenix from January 2017 to December 2019, as the Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix from July 2015 to December 2019, as the General Manager of Evolung, LLC (a subsidiary of United Therapeutics) from July 2013 to April 2014, as the Associate Director of Lung Transplant and Medical Director of Advanced Lung Disease at Norton Thoracic Institute from July 2011 to June 2013 and as Assistant Professor of Medicine at University of California, Los Angeles Lung Transplant and Pulmonary Hypertension Programs from June 2008 to June 2011. Dr. Saggar received a B.S. degree and a M.D. degree from the University of California, Irvine. He completed his residency in Internal Medicine at the University of California, Irvine, a fellowship in Pulmonary & Critical Care at the University of California, Irvine, and received subspecialty training in pulmonary hypertension and lung transplantation at University of California, San Diego and University of California, Los Angeles, respectively.- Rajeev Saggar，自2022年7月起担任首席医疗官，负责监督公司研究、临床开发、医疗事务和监管事务的各个方面。在加入Liquidia Corporation公司之前，Saggar博士于2020年1月至2022年7月在Theravance Biopharma任职，担任临床开发副总裁，负责监督呼吸道疾病组合的所有阶段临床开发，包括肺纤维化、同种异体移植排斥、哮喘、COPD和COVID-19。此前，Saggar博士还曾于2017年1月至2019年12月担任亚利桑那大学凤凰城医学院肺重症医学科的临时主管，于2015年7月至2019年12月担任凤凰城邦纳大学医学中心肺动脉高压和纤维化项目以及肺移植项目的医疗主任，于2013年7月至2014年12月担任Evolung，LLC（联合治疗的子公司）的总经理，2011年7月至2013年6月担任诺顿胸腔研究所肺移植副主任和晚期肺部疾病医学主任，2008年6月至2011年6月担任加州大学洛杉矶分校肺移植和肺动脉高压项目医学助理教授。Saggar博士获得了加州大学欧文分校的学士学位和医学博士学位。他在加州大学欧文分校完成了内科住院医师实习，在加州大学欧文分校完成了肺部和重症监护研究金，并分别在加州大学圣地亚哥分校和加州大学洛杉矶分校接受了肺动脉高压和肺移植方面的亚专科培训。
- Rajeev Saggar,has been Chief Medical Officer since July 2022 and oversees all aspects of research, clinical development, medical affairs, and regulatory affairs for the company. Prior to joining Liquidia Corporation company, Dr. Saggar was at Theravance Biopharma from January 2020 to July 2022, where he served as Vice President of Clinical Development, with oversight of all phases of clinical development across respiratory disease portfolio, including pulmonary fibrosis, allograft rejection, asthma, COPD, and COVID-19. Previously, Dr. Saggar also served as Interim Chief of the Division of Pulmonary Critical Care at University of Arizona, College of Medicine, Phoenix from January 2017 to December 2019, as the Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix from July 2015 to December 2019, as the General Manager of Evolung, LLC (a subsidiary of United Therapeutics) from July 2013 to April 2014, as the Associate Director of Lung Transplant and Medical Director of Advanced Lung Disease at Norton Thoracic Institute from July 2011 to June 2013 and as Assistant Professor of Medicine at University of California, Los Angeles Lung Transplant and Pulmonary Hypertension Programs from June 2008 to June 2011. Dr. Saggar received a B.S. degree and a M.D. degree from the University of California, Irvine. He completed his residency in Internal Medicine at the University of California, Irvine, a fellowship in Pulmonary & Critical Care at the University of California, Irvine, and received subspecialty training in pulmonary hypertension and lung transplantation at University of California, San Diego and University of California, Los Angeles, respectively.
- Scott Moomaw
Scott Moomaw，自2023年1月起担任首席商务官，在此之前担任高级副总裁，自2020年11月完成合并交易后商业生效。在加入Liquidia之前，Moomaw先生于2018年8月至2020年11月期间担任RareGen的首席运营官。Moomaw先生是一位经验丰富的生物制药领导者。他在推出产品、制定商业战略和组织方面拥有丰富的经验。在加入RAREGen之前，2016年10月至2018年8月，Moomaw先生担任OPKO保健 Health，Inc.（纳斯达克：OPK）的市场营销副总裁，这是一家专注于诊断和制药的医学测试和用药公司，在那里他推出了针对慢性肾病的专业产品。在加入OPKO保健之前，Moomaw先生在2011年1月至2016年5月期间担任生物技术公司联合治疗（纳斯达克：UTHR）的市场营销副总裁，在那里他领导了一系列治疗肺动脉高压的品牌。在加入联合治疗之前，从2000年到2010年，Moomaw先生在制药公司礼来和公司（纽约证券交易所代码：LLY）担任过各种销售和营销职务，责任越来越大。Moomaw先生毕业于迈阿密大学，获得理学学士学位，并拥有密歇根大学工商管理硕士学位。
Scott Moomaw,has been Chief Commercial Officer since January 2023 and before that served as Senior Vice President, Commercial effective upon consummation of the Merger Transaction in November 2020. Prior to Liquidia, Mr. Moomaw was RareGen's Chief Operating Officer from August 2018 until November 2020. Mr. Moomaw is a seasoned leader in biopharmaceuticals. He has extensive experience launching products and developing commercial strategies and organizations. Prior to joining RareGen, from October 2016 until August 2018, Mr. Moomaw was Vice President of Marketing of OPKO Health, Inc. (Nasdaq: OPK), a medical test and medication company focused on diagnostics and pharmaceuticals, where he launched a specialty product for chronic kidney disease. Prior to OPKO Health, Mr. Moomaw was Associate Vice President of Marketing at United Therapeutics (Nasdaq: UTHR), a biotechnology company, from January 2011 until May 2016, where he led a portfolio of brands to treat pulmonary hypertension. Prior to United Therapeutics, from 2000 until 2010, Mr. Moomaw held a variety of sales and marketing roles of increasing responsibility at Eli Lilly and Company (NYSE: LLY), a pharmaceutical company. Mr. Moomaw graduated with a Bachelor of Science from Miami University and he holds a Master's in Business Administration from the University of Michigan.- Scott Moomaw，自2023年1月起担任首席商务官，在此之前担任高级副总裁，自2020年11月完成合并交易后商业生效。在加入Liquidia之前，Moomaw先生于2018年8月至2020年11月期间担任RareGen的首席运营官。Moomaw先生是一位经验丰富的生物制药领导者。他在推出产品、制定商业战略和组织方面拥有丰富的经验。在加入RAREGen之前，2016年10月至2018年8月，Moomaw先生担任OPKO保健 Health，Inc.（纳斯达克：OPK）的市场营销副总裁，这是一家专注于诊断和制药的医学测试和用药公司，在那里他推出了针对慢性肾病的专业产品。在加入OPKO保健之前，Moomaw先生在2011年1月至2016年5月期间担任生物技术公司联合治疗（纳斯达克：UTHR）的市场营销副总裁，在那里他领导了一系列治疗肺动脉高压的品牌。在加入联合治疗之前，从2000年到2010年，Moomaw先生在制药公司礼来和公司（纽约证券交易所代码：LLY）担任过各种销售和营销职务，责任越来越大。Moomaw先生毕业于迈阿密大学，获得理学学士学位，并拥有密歇根大学工商管理硕士学位。
- Scott Moomaw,has been Chief Commercial Officer since January 2023 and before that served as Senior Vice President, Commercial effective upon consummation of the Merger Transaction in November 2020. Prior to Liquidia, Mr. Moomaw was RareGen's Chief Operating Officer from August 2018 until November 2020. Mr. Moomaw is a seasoned leader in biopharmaceuticals. He has extensive experience launching products and developing commercial strategies and organizations. Prior to joining RareGen, from October 2016 until August 2018, Mr. Moomaw was Vice President of Marketing of OPKO Health, Inc. (Nasdaq: OPK), a medical test and medication company focused on diagnostics and pharmaceuticals, where he launched a specialty product for chronic kidney disease. Prior to OPKO Health, Mr. Moomaw was Associate Vice President of Marketing at United Therapeutics (Nasdaq: UTHR), a biotechnology company, from January 2011 until May 2016, where he led a portfolio of brands to treat pulmonary hypertension. Prior to United Therapeutics, from 2000 until 2010, Mr. Moomaw held a variety of sales and marketing roles of increasing responsibility at Eli Lilly and Company (NYSE: LLY), a pharmaceutical company. Mr. Moomaw graduated with a Bachelor of Science from Miami University and he holds a Master's in Business Administration from the University of Michigan.
- Russell Schundler
Russell Schundler，自2021年3月起担任总法律顾问和秘书。Schundler先生于2020年2月至2021年3月期间担任PBM Capital Group，LLC（“PBM资本”）的总法律顾问，该公司是一家从事投资于医疗保健和生命科学相关公司业务的私募股权投资公司，并于2014年4月至2020年2月期间担任PBM资本的公司法律顾问。在加入PBM Capital之前，Schundler先生于2010年至2014年在Woods 罗杰斯 PLC、2007年至2010年在McGuireWoods LLP以及2001年至2007年在Woods 罗杰斯担任私人执业律师。Schundler先生拥有弗吉尼亚大学历史和经济学学士学位、弗吉尼亚大学法学院法学博士学位，并获得在弗吉尼亚州联邦从事法律业务的许可。
Russell Schundler,has been General Counsel and Secretary since March 2021. Mr. Schundler served as General Counsel of PBM Capital Group, LLC ("PBM Capital"), a private equity investment firm in the business of investing in healthcare and life-science related companies from February 2020 until March 2021, and served as Corporate Counsel of PBM Capital from April 2014 to February 2020. Prior to joining PBM Capital, Mr. Schundler was an attorney in private practice with Woods Rogers PLC from 2010 to 2014, McGuireWoods LLP from 2007 to 2010 and Woods Rogers from 2001 to 2007. Mr. Schundler holds a B.A. in history and economics from the University of Virginia, a J.D. from the University of Virginia School of Law and is licensed to practice law in the Commonwealth of Virginia.- Russell Schundler，自2021年3月起担任总法律顾问和秘书。Schundler先生于2020年2月至2021年3月期间担任PBM Capital Group，LLC（“PBM资本”）的总法律顾问，该公司是一家从事投资于医疗保健和生命科学相关公司业务的私募股权投资公司，并于2014年4月至2020年2月期间担任PBM资本的公司法律顾问。在加入PBM Capital之前，Schundler先生于2010年至2014年在Woods 罗杰斯 PLC、2007年至2010年在McGuireWoods LLP以及2001年至2007年在Woods 罗杰斯担任私人执业律师。Schundler先生拥有弗吉尼亚大学历史和经济学学士学位、弗吉尼亚大学法学院法学博士学位，并获得在弗吉尼亚州联邦从事法律业务的许可。
- Russell Schundler,has been General Counsel and Secretary since March 2021. Mr. Schundler served as General Counsel of PBM Capital Group, LLC ("PBM Capital"), a private equity investment firm in the business of investing in healthcare and life-science related companies from February 2020 until March 2021, and served as Corporate Counsel of PBM Capital from April 2014 to February 2020. Prior to joining PBM Capital, Mr. Schundler was an attorney in private practice with Woods Rogers PLC from 2010 to 2014, McGuireWoods LLP from 2007 to 2010 and Woods Rogers from 2001 to 2007. Mr. Schundler holds a B.A. in history and economics from the University of Virginia, a J.D. from the University of Virginia School of Law and is licensed to practice law in the Commonwealth of Virginia.
- Dana Boyle
达纳 Boyle，此前自2021年1月起担任公司高级副总裁、财务及财务总监。在加入公司之前，Boyle女士曾于2019年2月至2021年1月担任Aerami Therapeutics，Inc.的财务总监，该公司是一家前私营生物技术公司，专注于开发治疗严重呼吸道疾病（包括肺动脉高压）的改进疗法，并于2017年9月至2018年10月担任前专业制药公司Aralez制药公司的财务规划和分析总监。博伊尔女士的职业生涯始于德勤会计师事务所（Deloitte & Touche LLP）的审计师，拥有罗格斯大学会计学理学学士学位，是一名获得纽约州执照的注册会计师。
Dana Boyle,previously served as the Company's Senior Vice President, Finance and Controller since January 2021. Prior to joining the Company, Ms. Boyle served as Controller of Aerami Therapeutics, Inc., a former private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension, from February 2019 to January 2021, and served as the Director of Financial Planning and Analysis at Aralez Pharmaceuticals Inc., a former specialty pharmaceutical company, from September 2017 to October 2018. Ms. Boyle began her career as an auditor at Deloitte & Touche LLP, holds a Bachelor of Science in accounting from Rutgers University and is a certified public accountant licensed in the state of New York.- 达纳 Boyle，此前自2021年1月起担任公司高级副总裁、财务及财务总监。在加入公司之前，Boyle女士曾于2019年2月至2021年1月担任Aerami Therapeutics，Inc.的财务总监，该公司是一家前私营生物技术公司，专注于开发治疗严重呼吸道疾病（包括肺动脉高压）的改进疗法，并于2017年9月至2018年10月担任前专业制药公司Aralez制药公司的财务规划和分析总监。博伊尔女士的职业生涯始于德勤会计师事务所（Deloitte & Touche LLP）的审计师，拥有罗格斯大学会计学理学学士学位，是一名获得纽约州执照的注册会计师。
- Dana Boyle,previously served as the Company's Senior Vice President, Finance and Controller since January 2021. Prior to joining the Company, Ms. Boyle served as Controller of Aerami Therapeutics, Inc., a former private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension, from February 2019 to January 2021, and served as the Director of Financial Planning and Analysis at Aralez Pharmaceuticals Inc., a former specialty pharmaceutical company, from September 2017 to October 2018. Ms. Boyle began her career as an auditor at Deloitte & Touche LLP, holds a Bachelor of Science in accounting from Rutgers University and is a certified public accountant licensed in the state of New York.